Effects of two novel nucleoside analogues on different hepatitis B virus promoters

Table 2 Effect-dosage relationship of the inhibition of the expression of EGFP under the control of the Sp and Xp promoters by β-L-D4A

Dosage (&mgr;mol/L)	n	EGFP-positive cells (%) (mean ± SD)		Inhibition rate (%)
		Sp	Xp	Sp	Xp
Control	3	21.26 ± 0.25	18.52 ± 1.25	0.0	0.0
(Lamivudine)	4	21.00 ± 0.43	18.37 ± 1.01	1.2	0.8
0.08	4	18.76 ± 0.41b	16.47 ± 0.49b	11.8	11.1
0.4	4	17.31 ± 0.41b	15.68 ± 0.36b	18.6	15.3
2	4	15.54 ± 0.48b	13.54 ± 0.59b	26.9	26.9
10	4	11.33 ± 0.32b	10.84 ± 0.81b	46.7	41.5

^bP < 0.01 vs Blank control. EGFP: Enhanced green fluorescent protein.